Strontium ranelate: The first agent of a new therapeutic class in osteoporosis.

[en] Strontium ranelate is a new agent developed for the management of post-menopausal osteoporosis. It has a unique mode of action, based on an uncoupling between bone formation (increased) and bone resorption (decreased). To review its effectiveness we searched the MEDLINE database from 1985 to 2008, as well as databases such as the Cochrane controlled register, for citations or relevant articles. After this extensive search of the literature, a critical appraisal of the data was obtained through a consensus meeting (AN, MH, SS, OB, and J-YR). We found that strontium ranelate reduces vertebral, nonvertebral, major nonvertebral, and hip fractures over 1, 3, 4, and 5 years. Its spectrum of activity covers women with osteopenia, osteoporosis, and severe osteoporosis. Elderly subjects also show a reduction in vertebral and nonvertebral fractures. Bone mineral density may be used as a monitoring tool for strontium ranelate, since early changes are predictive of long-term fracture reduction. Biochemical markers of bone turnover reflect the uncoupling between resorption and formation. The safety profile of strontium ranelate compares favorably with the other currently marketed antiosteoporosis medications. Preliminary results suggest that strontium ranelate is able to reduce the progression of spine osteoarthritis. In conclusion, strontium ranelate has the potential to be a candidate for first-line treatment of osteopenia and osteoporosis. However, further research is needed before suggesting its widespread use in osteoarthritis.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

NEUPREZ, Audrey ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidemiologie et santé publique

Hiligsmann, Mickaël ; Université de Liège - ULiège > HEC - École de gestion de l'ULiège > Economie industrielle

Scholtissen, Sophie ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique - Département des sciences de la santé publique

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Language :

English

Title :

Strontium ranelate: The first agent of a new therapeutic class in osteoporosis.

Publication date :

2008

Journal title :

Advances in Therapy

ISSN :

0741-238X

eISSN :

1865-8652

Publisher :

Springer, New York, United States - New York

Volume :

Issue :

Pages :

1235-56

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 07 April 2009

Statistics

Number of views

78 (8 by ULiège)

Number of downloads

3 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Cooper C, Westlake S, Harvey N, et al. Review: developmental origins of osteoporotic fracture. Osteoporos Int. 2006;17:337-347.
Russell RGG. Pathogenesis of osteoporosis. In: Hochberg MC, Siman AJ, Smolen SJ, Weinblatt ME, Weisman MH, eds. Rheumatology. 3rd edition. New York: Mosby; 2003:2075-2147.
Marie PJ, Hott M, Modrowski D, DePollak, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-defcient rats. J Bone Miner Res.1993;8:607-615. (Pubitemid 23127921)
Canalis E, Hott M, Delofre P, Tsouderos Y, Marie PJ. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone. 1996;18:517-523. (Pubitemid 26257871)
Reginster JY, Sarlet N, Lejeune E, Leonori L. Strontium ranelate: a new treatment for postmenopausal osteoporosis with a dual mode of action. Curr Osteoporos Rep. 2005;3:30-34.
Reginster JY. Strontium ranelate in osteoporosis. Curr Pharm Des. 2002;8: 1907-1916.
Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int. 2001;69:121-129. (Pubitemid 32912229)
Boivin G, Delofre P, Perrat B, et al. Strontium distribution and interactions with bone mineral in monkey iliarc bone afer strontium salt (S12911) administration. J Bone Miner Res. 1996;11:1302-1311. (Pubitemid 26282531)
Atkins GJ, Welldon KJ, Halbout P, Findlay DM. Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting and osteoprotegerin response. Osteoporos Int. 2008. In press.
Kendler D. Strontium ranelate-data on vertebral and nonvertebral fracture efcacy and safety: mechanism of action. Curr Osteoporos Rep. 2006;4:34-39. (Pubitemid 44623946)
Morohashi T, Sano T, Harai K, Yamada S. Effects of strontium on calcium metabolism in rats-II. Strontium prevents the increased rate of bone turnover in ovariectomized rats. Jpn J Pharmacol. 1995;68:153-159.
Marie P. Strontium ranelate: a physiological approach for optimizing bone formation and resorption. Bone. 2006;38 (suppl. 1):S10-S14. (Pubitemid 43190768)
Ammann P. Strontium ranelate: a physiological approach for an improved bone quality. Bone. 2006;38 (suppl. 1):S15-S18. (Pubitemid 43190769)
Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C. Prevention of early postmenopausal bone loss by strontium ranelate: a randomized, two-year, double-blind, dose-ranging, placebo-controlled trial. Osteoporos Int. 2002;13:925-931. (Pubitemid 36050269)
Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent Effects in established postmenopausal vertebral osteoporosis: a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab. 2002;87:2060-2066. (Pubitemid 34521489)
Boivin G, Foos E, Tupinon-Mathieu I, Meunier PJ. Strontium deposition in bone is dose dependent and does not alter the degree of mineralization of bone in osteoporotic patients treated with strontium ranelate. J Bone Miner Res. 2000;15(suppl. 1):305.
Meunier PJ, Roux C, Seeman E, et al. The Effect of strontium ranelate on the risk of vertebral fracture in women with post menopausal osteoporosis. N Engl J Med. 2004;350:459-468. (Pubitemid 38133766)
Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90: 2816-2822. (Pubitemid 40686329)
Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis. Arthritis Rheum. 2008;58:1687-1695.
Meunier PJ, Reginster JY. Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporos Int. 2003;14 (suppl. 3): 66-76.
Reginster J Y, Spector T, Badurski J, et al. A short-term run-in study can signifcantly contribute to increasing the quality of long-term osteoporosis trials. The strontium ranelate phase III program. Osteoporos Int. 2002;13(suppl. 1):S30.
Genant HK, Wu CY, Van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148. (Pubitemid 23261108)
Meunier PJ, Roux C, Ortolani S, et al. Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis. Osteoporos Int. 2002;13 (suppl. 1):O45.
Roux C, Reginster JY, Fechtenbaum J, et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res. 2006;21:536-542.
Naves M, Diaz Lopez JB, Gomez C, Rodriguez Rebollar A, Rodriguez Garcia M, Cannata Andia JB. The Effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population. Osteoporos Int. 2003;14:520-524. (Pubitemid 36919214)
van Staa TP, Leufens HGM, Cooper C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int. 2002;13:624-629.
Roux C, Fechtenbaum J, Kolta S, Isaia G, Cannata Andia JB, Devogelaer JP. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis. 2008;67:1736-1738.
Population Division of the Department of Economic and Social Afairs of the Nations Secretariat 2002. World population prospects: the 2002 revision and world urban prospects. Available at: www.esa. un.org. Accessed October 1, 2008.
Ettinger MP. Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Arch Intern Med. 2003;163: 2237-2246. (Pubitemid 37248789)
McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. N Engl J Med. 2001;344:333-340. (Pubitemid 32107641)
Seeman E, Vellas B, Benhamou C, et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res. 2006;21:1113-1120.
Seeman E, Devogelaer J, Lorenc R, et al. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res. 2008;23:433-438. (Pubitemid 351304674)
Malaise O, Bruyere O, Reginster JY. Strontium ranelate normalizes bone mineral density in osteopenic patients. Aging Clin Exp Res. 2007;19:330-333. (Pubitemid 47496895)
Reginster JY, Meunier PJ. Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporos Int. 2003;14:S56-S65.
Bruyere O, Roux C, Detilleux J, et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab. 2007;92:3076-3081. (Pubitemid 47236373)
Bruyere O, Roux C, Badurski J, et al. Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin. 2007;23: 3041-3045.
Arlot ME, Jiang Y, Genant HK, et al. Histomorphometric and μ-CT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res. 2008;23:215-222. (Pubitemid 351160035)
de la Loge C, Sullivan K, Pinkney R, Marquis P, Roux C, Meunier PJ. Cross-cultural validation and analysis of responsiveness of the QUALIOST ®: QUAlity of Life questionnaire In OSTeoporosis. Health Qual Life Outcomes. 2005;3:69.
Marquis P, de la Loge C, Diaz-Curiel M, Spector T, Meunier PJ. Benefcial Effects of strontium ranelate on the quality of life in patients with vertebral osteoporosis (SOTI study). Osteoporos Int. 2005;16:S54
Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778-799. (Pubitemid 28225778)
Recommendations for the registration of drugs used in the treatment of osteoarthritis. Group for the Respect of Ethics and Excellence in Science (GREES): osteoarthritis section. Ann Rheum Dis. 1996;55:552-557.
Altman R, Brandt K, Hochberg M, et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cartilage. 1996;4:217-243. (Pubitemid 26408292)
Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M. Evaluation of the structure-modifying Effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating Effect of diacerein in OA of the hip. Arthritis Rheum. 2001;44:2539-2547. (Pubitemid 33049332)
Reginster JY, Deroisy R, Rovati LC, et al. Long-term Effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357:251-256. (Pubitemid 32120855)
Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162:2113-2123. (Pubitemid 35168220)
Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 2005;52:779-786. (Pubitemid 40365099)
Uebelhart D, Malaise M, Marcolongo R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage. 2004;12:269-276. (Pubitemid 38461289)
Brandt KD, Mazzuca SA, Katz BP, et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo controlled, double-blind trial. Arthritis Rheum. 2005;52:2015-2025. (Pubitemid 40994324)
Neogi T, Nevitt MC, Ensrud KE, Bauer D, Felson DT. The Effect of alendronate on progression of spinal osteophytes. Arthritis Rheum. 2006;54(suppl.):S822.
Martel-Pelletier J, Lajeunesse D, Fahmi H, Tardif G, Pelletier JP. New thoughts on the pathophysiology of osteoarthritis: one more step toward new therapeutic targets. Curr Rheumatol Rep. 2006;8:30-36. (Pubitemid 44659357)
Henrotin Y, Labasse A, Zheng SX, et al. Strontium ranelate increases cartilage matrix formation. J Bone Miner Res. 2001;16: 299-308. (Pubitemid 32105411)
Alexanderson P, Karsdal M, Qvist P, Reginster JY, Christiansen C. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. Bone. 2007;40: 218-222. (Pubitemid 44848419)
Bruyere O, Delferriere D, Roux C, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis. 2008;67;335-339. (Pubitemid 351281267)
Lane NE, Nevitt MC, Genant HK, Hochberg MC. Reliability of new indices of radiographic osteoarthritis of the hand and hip and lumbar disc degeneration. J Rheumatol. 1993;20:1911-1918. (Pubitemid 24031597)
Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L. Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol. 2008;66:689-694.
Shea B, Wells G, Cranney A, et al. Osteoporosis Methodology Group; Osteoporosis Research Advisory Group. Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev. 2004;(1):CD004526.
Question and answers on the safety of Protelos/Osseor (strontium ranelate). London: European Medicines Agency; 2007. Ref. EMEA/534613/2007. Available at: www.emea.europa.eu/humandocs/PDFs/EPAR/protelos/Protelos-Q&A- 53461307en.pdf. Accessed October 1, 2008.
Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology. 2003;206:353-356. (Pubitemid 36677029)